-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
-
Primary results for SOLSTICE and VISTA to be shared for the first time
Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.
-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Experts to discuss AIDING results for automated insulin delivery in the hospital
Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes.
-
Symposium to highlight the latest chapters in the Standards of Care for Overweight and Obesity
The American Diabetes Association® (ADA) released the first chapters of this document in 2025. Kimberly Gudzune, MD, MPH, and other speakers will explain new standards on the screening and diagnosis of obesity, and on pharmacological treatments.
-
Panel discussion to explore stem cell-derived beta cell therapy for type 1 diabetes
Sanjoy Dutta, PhD, Jay Skyler, MD, and other panelists will share insights on advances in the use of manufactured islets and what it might take to achieve widespread clinical use.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.
-
Maximize your Scientific Sessions experience through engagement
Rita R. Kalyani, MD, MHS, the ADA’s Chief Scientific and Medical Officer, encourages participants in New Orleans to come ready to delve deeper into their core areas of expertise and to seize opportunities to explore new ideas.
-
Join the ADA in New Orleans for the 2026 Scientific Sessions
Experts from across the globe will convene to share the latest cutting-edge advances in diabetes research, prevention, and care June 5–8 as part of an education program featuring 200 sessions across 25 topic areas.
-
Expand your network within the diabetes community
Attendees of the 2026 Scientific Sessions will have several opportunities to engage with other diabetes professionals, starting with Friday evening’s Networking Reception.